Cutaneous T-cell lymphoma.
Cutaneous T-cell lymphoma (CTCL) represents a spectrum of the non-Hodgkin's lymphomas, including mycosis fungoides (MFs) and Sezary syndrome. Although an uncommon malignancy, the number of new cases per year in the United States is increasing at a constant rate. This paper provides an overview of CTCL, including pathophysiology, information on the various treatment modalities, and practical clinical approaches needed by oncology nurses to assist individuals experiencing treatment-related toxicities. Psychosocial issues, an aspect of disease in which oncology nurses can provide support and understanding, also are addressed.
Gilyon
K
K
Alta Bates-Herrick Hospital, Berkeley, CA.
Kuzel
T M
TM
D000287:Administration, Topical; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D007370:Interferon Type I / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000451:nursing / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011701:PUVA Therapy; D010353:Patient Education as Topic; D011878:Radiotherapy
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007370:Interferon Type I